In agreement with clinical observations, patients with AML frequently relapse after chemotherapy, and mutations or alterations in hENT1 and dCK are among the most common findings in AML patient samples [24] and cell lines [13,32,33,34]. This evidence concerns the gene DCK and acute myeloid leukemia.